Details of the Drug Combination

General Information of Drug Combination (ID: DCP5HZ3)

• Drug Combination Name: ABIRATERONE + Raloxifene
• Indication: Invasive ductal carcinoma; Status: Investigative [1]
• Component Drugs:
  ABIRATERONE (DM8V75C): Small molecular drug
  Raloxifene (DMDKF3M): Small molecular drug
• High-throughput Screening Result:
  Testing Cell Line: HS 578T
  Zero Interaction Potency (ZIP) Score: 2.16
  Bliss Independence Score: 9.12
  Loewe Additivity Score: 2.6
  LHighest Single Agent (HSA) Score: 3.82

Molecular Interaction Atlas of This Drug Combination

Indication(s) of ABIRATERONE

Disease Entry	ICD 11	Status	REF
Prostate cancer	2C82.0	Approved	[2]

ABIRATERONE Interacts with 1 DTT Molecule(s)

DTT Name	DTT ID	UniProt ID	Mode of Action	REF
Steroid 17-alpha-monooxygenase (S17AH)	TTRA5BZ	CP17A_HUMAN	Modulator	[4]

ABIRATERONE Interacts with 4 DOT Molecule(s)

DOT Name	DOT ID	UniProt ID	Mode of Action	REF
Steroid 17-alpha-hydroxylase/17,20 lyase (CYP17A1)	OTZKVLVJ	CP17A_HUMAN	Decreases Activity	[5]
Tissue factor (F3)	OT3MSU3B	TF_HUMAN	Increases Expression	[6]
Membrane cofactor protein (CD46)	OTQ8NWJD	MCP_HUMAN	Increases Expression	[7]
Androgen receptor (AR)	OTUBKAZZ	ANDR_HUMAN	Decreases Response To Substance	[8]

Indication(s) of Raloxifene

Disease Entry	ICD 11	Status	REF
Osteoporosis	FB83.0	Approved	[3]

Raloxifene Interacts with 1 DTT Molecule(s)

DTT Name	DTT ID	UniProt ID	Mode of Action	REF
Estrogen receptor (ESR)	TTZAYWL	ESR1_HUMAN	Modulator	[9]

Raloxifene Interacts with 1 DTP Molecule(s)

DTP Name	DTP ID	UniProt ID	Mode of Action	REF
P-glycoprotein 1 (ABCB1)	DTUGYRD	MDR1_HUMAN	Substrate	[10]

Raloxifene Interacts with 3 DME Molecule(s)

DME Name	DME ID	UniProt ID	Mode of Action	REF
Cytochrome P450 3A4 (CYP3A4)	DE4LYSA	CP3A4_HUMAN	Metabolism	[11]
UDP-glucuronosyltransferase 1A1 (UGT1A1)	DEYGVN4	UD11_HUMAN	Metabolism	[12]
UDP-glucuronosyltransferase 1A10 (UGT1A10)	DEL5N6Y	UD110_HUMAN	Metabolism	[13]

Test Results of This Drug Combination in Other Disease Systems

Indication	DrugCom ID	Cell Line	Status	REF
Adult acute myeloid leukemia	DCSACHY	HL-60(TB)	Investigative	[14]
Astrocytoma	DCTM6FL	SNB-19	Investigative	[14]
Childhood T acute lymphoblastic leukemia	DCXQMD7	CCRF-CEM	Investigative	[14]
Chronic myelogenous leukemia	DCQ14AB	K-562	Investigative	[14]
Clear cell renal cell carcinoma	DCMR12C	A498	Investigative	[14]
Clear cell renal cell carcinoma	DCV3SQE	TK-10	Investigative	[14]
Glioblastoma	DCKNT1B	SNB-75	Investigative	[14]
Glioma	DCR5M3A	SF-268	Investigative	[14]
Carcinoma	DCELGUC	MCF7	Investigative	[1]
Colon adenocarcinoma	DC8S136	COLO 205	Investigative	[1]
Invasive ductal carcinoma	DCK4XNC	BT-549	Investigative	[1]
Invasive ductal carcinoma	DC03WRB	T-47D	Investigative	[1]
Adenocarcinoma	DCLHYLO	DU-145	Investigative	[15]
Adenocarcinoma	DCJC9CL	NCIH23	Investigative	[15]
Adenocarcinoma	DCCLFLB	HT29	Investigative	[15]
Adenocarcinoma	DC8A96I	HCT116	Investigative	[15]
Amelanotic melanoma	DC58G3J	MDA-MB-435	Investigative	[15]
Amelanotic melanoma	DCNG3B5	M14	Investigative	[15]
Cutaneous melanoma	DCKWIP2	SK-MEL-28	Investigative	[15]
High grade ovarian serous adenocarcinoma	DCAPMSM	OVCAR-8	Investigative	[15]
High grade ovarian serous adenocarcinoma	DCLXAAQ	OVCAR-5	Investigative	[15]
Large cell lung carcinoma	DC7OCPC	NCI-H460	Investigative	[15]
Lung adenocarcinoma	DCML8JI	HOP-62	Investigative	[15]
Lung adenocarcinoma	DCXDUSI	EKVX	Investigative	[15]
Lung adenocarcinoma	DCNCBQ9	NCI-H522	Investigative	[15]
Melanoma	DCMN4MU	SK-MEL-2	Investigative	[15]
Melanoma	DCYL1PB	MALME-3M	Investigative	[15]
Minimally invasive lung adenocarcinoma	DCY2CUS	NCI-H322M	Investigative	[15]
Non-small cell lung carcinoma	DC8IZGS	HOP-92	Investigative	[15]
Ovarian serous cystadenocarcinoma	DCBT4M9	SK-OV-3	Investigative	[15]
Pleural epithelioid mesothelioma	DCFY0Q5	NCI-H226	Investigative	[15]

References

• [1] Biologically active neutrophil chemokine pattern in tonsillitis.Clin Exp Immunol. 2004 Mar;135(3):511-8. doi: 10.1111/j.1365-2249.2003.02390.x.
• [2] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6745).
• [3] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
• [4] 2011 FDA drug approvals. Nat Rev Drug Discov. 2012 Feb 1;11(2):91-4.
• [5] A fission yeast-based test system for the determination of IC50 values of anti-prostate tumor drugs acting on CYP21. J Enzyme Inhib Med Chem. 2006 Oct;21(5):547-56.
• [6] Elucidating mechanisms of toxicity using phenotypic data from primary human cell systems--a chemical biology approach for thrombosis-related side effects. Int J Mol Sci. 2015 Jan 5;16(1):1008-29. doi: 10.3390/ijms16011008.
• [7] Targeting CD46 for both adenocarcinoma and neuroendocrine prostate cancer. JCI Insight. 2018 Sep 6;3(17):e121497. doi: 10.1172/jci.insight.121497. eCollection 2018 Sep 6.
• [8] Targeting chromatin binding regulation of constitutively active AR variants to overcome prostate cancer resistance to endocrine-based therapies. Nucleic Acids Res. 2015 Jul 13;43(12):5880-97. doi: 10.1093/nar/gkv262. Epub 2015 Apr 23.
• [9] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 620).
• [10] Influence of hepatic and intestinal efflux transporters and their genetic variants on the pharmacokinetics and pharmacodynamics of raloxifene in osteoporosis treatment. Transl Res. 2012 Oct;160(4):298-308.
• [11] The role of P-glycoprotein in the bioactivation of raloxifene. Drug Metab Dispos. 2006 Dec;34(12):2073-8.
• [12] Drug-drug interactions for UDP-glucuronosyltransferase substrates: a pharmacokinetic explanation for typically observed low exposure (AUCi/AUC) ratios. Drug Metab Dispos. 2004 Nov;32(11):1201-8.
• [13] Characterization of raloxifene glucuronidation: potential role of UGT1A8 genotype on raloxifene metabolism in vivo. Cancer Prev Res (Phila). 2013 Jul;6(7):719-30.
• [14] Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
• [15] Loss of function mutations in VARS encoding cytoplasmic valyl-tRNA synthetase cause microcephaly, seizures, and progressive cerebral atrophy.Hum Genet. 2018 Apr;137(4):293-303. doi: 10.1007/s00439-018-1882-3. Epub 2018 Apr 24.